Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions
- Acronyms DYNAMIC
- Sponsors Capricor Therapeutics
- 31 Oct 2016 Top-line 12-month data from this trial was announced in June 2016, according to a Capricor Therapeutics media release.
- 31 Oct 2016 Results published in the Capricor Pharmaceuticals media release.
- 17 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2020.